A genetic test could aid the identification of men with prostate cancer who are most likely to benefit from immunotherapy.
Browsing: Taxonomy > Immunotherapy
A first-of-its-kind vaccine, termed AST-VAC2, has moved into a Phase I clinical trial for non-small cell lung cancer patients.
A study presented at the American Society of Clinical Oncology Annual Meeting (ASCO, 1–5 June 2018, IL, USA) has revealed…
In a medical breakthrough, a new approach to immunotherapy has led to complete regression of breast cancer in a patient unresponsive to all other treatments.
Roche has announced results from its Phase III IMpower130 trial. The findings demonstrate that Tecentriq® plus chemotherapy helped individuals with metastatic non-squamous NSCLC, who lived significantly longer compared with those who received chemotherapy alone
Discover the case of nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer in this article from the impactful journal Immunotherapy.
Keytruda® has significantly improved overall survival and progression-free survival as a first-line treatment for squamous non-small cell lung cancer in the Phase III KEYNOTE-407 trial.
NICE have approved Tecentriq® (atezolizumab), for NHS patients with advanced bladder cancer who have relapsed following prior treatment.
In this interview discover some of the challenges in developing CAR-T therapies for solid tumors as well as major milestones in their development and where the field is heading.